These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 26403973)

  • 1. Denosumab: a new agent in the management of hypercalcemia of malignancy.
    Thosani S; Hu MI
    Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Hypercalcemia of Malignancy.
    Chakhtoura M; El-Hajj Fuleihan G
    Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab in hypercalcemia of malignancy: a case series.
    Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
    J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Denosumab normalized plasma calcium concentration in malignancy-associated hypercalcaemia].
    Størling L; Villadsen GE; Krogh K; Vestergaard P
    Ugeskr Laeger; 2014 Jul; 176(30):. PubMed ID: 25292242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
    Tai N; Inoue D
    Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab for treatment of hypercalcemia of malignancy.
    Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
    Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N
    Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypercalcemia of Malignancy.
    Hu MI
    Endocrinol Metab Clin North Am; 2021 Dec; 50(4):721-728. PubMed ID: 34774243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
    Hu MI; Glezerman I; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Ying W; Jain RK
    J Natl Cancer Inst; 2013 Sep; 105(18):1417-20. PubMed ID: 23990665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults.
    Seisa MO; Nayfeh T; Hasan B; Firwana M; Saadi S; Mushannen A; Shah SH; Rajjoub NS; Farah MH; Prokop LJ; Wang Z; Fuleihan GE; Drake MT; Murad MH
    J Clin Endocrinol Metab; 2023 Feb; 108(3):585-591. PubMed ID: 36545700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
    Uchida T; Yamaguchi H; Kushima C; Yonekawa T; Nakazato M
    Endocr J; 2020 Jan; 67(1):31-35. PubMed ID: 31527321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient.
    Dahmani O; Sophoclis C; Kebir M; Bouguern D; Sakho A; Demarchi P
    Saudi J Kidney Dis Transpl; 2017; 28(1):154-157. PubMed ID: 28098117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism.
    Pratt RM; West ML; Tennankore KK
    Perit Dial Int; 2020 Jan; 40(1):103-106. PubMed ID: 32063140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral Hypercalcemia in a Patient with Cholangiocellular Carcinoma - Effective Therapy with Denosumab.
    Harsch IA; Konturek PC
    Am J Case Rep; 2019 Sep; 20():1325-1330. PubMed ID: 31492829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma.
    Çalapkulu M; Gul OO; Cander S; Ersoy C; Erturk E; Sagiroglu MF; Saraydaroglu O
    J Coll Physicians Surg Pak; 2020 Jul; 30(7):757-759. PubMed ID: 32811610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.
    El-Hajj Fuleihan G; Clines GA; Hu MI; Marcocci C; Murad MH; Piggott T; Van Poznak C; Wu JY; Drake MT
    J Clin Endocrinol Metab; 2023 Feb; 108(3):507-528. PubMed ID: 36545746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe hypercalcemia following denosumab treatment in a juvenile patient.
    Setsu N; Kobayashi E; Asano N; Yasui N; Kawamoto H; Kawai A; Horiuchi K
    J Bone Miner Metab; 2016 Jan; 34(1):118-22. PubMed ID: 26056018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RE: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
    Adhikaree J; Newby Y; Sundar S
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663690
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
    Tsuda M; Ishiguro H; Yano I; Toi M
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906398
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of hypercalcaemia of malignancy in adults.
    Mc Donald D; Drake MT; Crowley RK
    Clin Med (Lond); 2023 Sep; 23(5):503-507. PubMed ID: 37775175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.